Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Receivables (2016 - 2025)

Cytokinetics (CYTK) has disclosed Receivables for 10 consecutive years, with $17.8 million as the latest value for Q4 2025.

  • Quarterly Receivables changed N/A to $17.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $17.8 million for FY2025, N/A changed from the prior year.
  • Receivables for Q4 2025 was $17.8 million at Cytokinetics, up from $1.8 million in the prior quarter.
  • The five-year high for Receivables was $51.8 million in Q4 2021, with the low at $147000.0 in Q4 2022.
  • Average Receivables over 5 years is $5.9 million, with a median of $2.0 million recorded in 2022.
  • The sharpest move saw Receivables soared 1072.38% in 2021, then crashed 99.72% in 2022.
  • Over 5 years, Receivables stood at $51.8 million in 2021, then plummeted by 99.72% to $147000.0 in 2022, then soared by 772.79% to $1.3 million in 2023, then plummeted by 80.98% to $244000.0 in 2024, then soared by 7180.33% to $17.8 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $17.8 million, $1.8 million, and $8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.